Form 4: Jazz Pharmaceuticals Director Sells Shares

Jazz Pharmaceuticals Director Bruce C. Cozadd sold 6,000 ordinary shares on July 1, 2026, under a pre-arranged 10b5-1 trading plan.

Summary

• Bruce C. Cozadd, a Director at Jazz Pharmaceuticals plc, reported a transaction involving the sale of 6,000 ordinary shares.
• The sale occurred on July 1, 2026, at a price of $240.47 per share.
• This transaction was executed under a written trading plan adopted on November 26, 2025, in accordance with Rule 10b5-1(c) of the Securities Exchange Act of 1934.
• The plan is designed to satisfy affirmative defense conditions, indicating the transaction was not discretionary.
• Following this sale, Mr. Cozadd beneficially owns 366,682 ordinary shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While a director sale can be a negative signal, the execution under a Rule 10b5-1 plan indicates it was pre-planned and not based on current, non-public information.

Negatives

• Director sale of shares, though executed under a 10b5-1 plan, can sometimes be perceived negatively by the market.

Future Outlook

No forward-looking statements or guidance are present in this filing.

Industry Context

StockSavvy.ai notes that Form 4 filings, particularly those involving director sales, are closely watched by investors. While this transaction was conducted under a pre-established 10b5-1 plan, which is designed to mitigate insider trading concerns, any significant insider selling can still influence market perception.

Stakeholder Impact

• Shareholders may view the sale, even if pre-planned, with caution, potentially leading to short-term price pressure.

Key Dates

Keywords

Jazz Pharmaceuticals, JAZZ, Form 4, Insider Trading, Share Sale, 10b5-1 Plan, Director Transaction, Beneficial Ownership